Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Want to learn more about implementing digital-first health solutions
Accessed July 2, 2026
Still, just a small percentage of people have used GLP-1 agonists and many do not know much about them
Studies such as the LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown reductions in major adverse cardiovascular events, including heart attack and stroke, in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk
It activates one of the body's master regulators of metabolism, an enzyme called AMP kinase, triggering some of the same benefits that fasting and exercise provide to our cells
US$ 25.29
US$ 28.76
US$ 21.96
US$ 27.23
US$ 29.55
